Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, of HBI-002, an Oral Low-dose Carbon Monoxide (CO) Liquid Drug Product, Administered Daily Over 14 Days in Subjects With Parkinson's Disease (PD)

Next Previous
Trial Profile

A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, of HBI-002, an Oral Low-dose Carbon Monoxide (CO) Liquid Drug Product, Administered Daily Over 14 Days in Subjects With Parkinson's Disease (PD)

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carbon monoxide (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Acronyms LoCaMoTE-PD
  • Sponsors Hillhurst Biopharmaceuticals

Most Recent Events

  • 05 Jun 2025 Status changed from planning to not yet recruiting.
  • 08 May 2025 According to a Hillhurst Biopharmaceuticals media release, company today announced , it received $6.3 million in grant awards to fund its Phase 2a clinical study in Parkinson's disease from The Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Farmer Family Foundation in conjunction with Massachusetts General Hospital.
  • 08 May 2025 According to a Hillhurst Biopharmaceuticals media release, this trial is scheduled to begin in early 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top